TY - JOUR TI - Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series AU - Hashemian, Seyed-Mohammad Reza AU - Aliannejad, Rasoul AU - Zarrabi, Morteza AU - Soleimani, Masoud AU - Vosough, Massoud AU - Hosseini, Seyedeh-Esmat AU - Hossieni, Hamed AU - Keshel, Saeid Heidari AU - Naderpour, Zeinab AU - Hajizadeh-Saffar, Ensiyeh AU - Shajareh, Elham AU - Jamaati, Hamidreza AU - Soufi-Zomorrod, Mina AU - Khavandgar, Naghmeh AU - Alemi, Hediyeh AU - Karimi, Aliasghar AU - Pak, Neda AU - Rouzbahani, Negin Hossieni AU - Nouri, Masoumeh AU - Sorouri, Majid AU - Kashani, Ladan AU - Madani, Hoda AU - Aghdami, Nasser AU - Vasei, Mohammad AU - Baharvand, Hossein T2 - Stem Cell Research & Therapy AB - Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human mesenchymal stem cells (MSCs) as a potential treatment for ARDS. In this phase 1 clinical trial, we present the safety, feasibility, and tolerability of the multiple infusions of high dose MSCs, which originated from the placenta and umbilical cord, in critically ill COVID-19-induced ARDS patients. DA - 2021/01/29/ PY - 2021 DO - 10.1186/s13287-021-02165-4 DP - BioMed Central VL - 12 IS - 1 SP - 91 J2 - Stem Cell Research & Therapy SN - 1757-6512 ST - Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients UR - https://doi.org/10.1186/s13287-021-02165-4 Y2 - 2021/02/09/17:11:22 KW - Acute respiratory distress syndrome KW - COVID-19 KW - Cell therapy KW - Mesenchymal stromal cells KW - Placenta KW - Pneumonia KW - SARS-CoV-2 KW - Umbilical cord ER -